This product is a bisphosphonate bone resorption inhibitor, which may mainly produce anti-bone resorption effect by binding to hydroxyapatite in the bone, inhibiting the dissolution and formation of hydroxyapatite.

This product is a bisphosphonate bone resorption inhibitor, which may mainly produce anti-bone resorption effect by binding to hydroxyapatite in the bone, inhibiting the dissolution and formation of hydroxyapatite.

This product is a bisphosphonate bone resorption inhibitor, which may mainly produce anti-bone resorption effect by binding to hydroxyapatite in the bone, inhibiting the dissolution and formation of hydroxyapatite.

Dabigatran and its acetylglucuronide conjugates are competitive direct thrombin inhibitors. They can prevent thrombosis by inhibiting thrombin, and their active groups can also inhibit free thrombin, thrombin bound to blood clots, and thrombin-induced platelet aggregation.

It produces bactericidal effects by inhibiting bacterial protein synthesis and has a strong antibacterial effect on a series of Gram-positive bacteria. Staphylococci, including strains resistant to penicillin, methicillin and other antibiotics, are highly sensitive to this product. There is no cross-resistance with other antibacterial drugs used in clinical practice, and the toxicity is extremely low, there is no cross-allergy, and it can be used to treat patients who are contraindicated to other antibiotics. It can be used in combination with other anti-staphylococcal drugs to reduce the development of drug resistance, and combined with other multiple antibiotics to achieve additive or synergistic effects.